Zydus Therapeutics, Inc.

Zydus Therapeutics Presents Phase 2b Data at AASLD 2026 Showing Greater Resolution of Steatohepatitis Without Worsening of Fibrosis With Investigational Saroglitazar Compared to Placebo in Adults With MASH and Fibrosis

Resolution of steatohepatitis without worsening of fibrosis was achieved by 39.1% of patients receiving saroglitazar magnesium 4 mg and 32.4%…